Research signals
Anti-tau antibody trials have grown substantially since 2024. Historical pattern scores for tau-targeting trials range 37 to 48% based on analogous completed trials, not a forecast. View full research signals ->
Tracked biomarkers
Tau PETStrong evidence
Detects Alzheimer's pathology 10 to 15 years before symptom onset. Gold standard research biomarker.
p-tau217 (plasma)Strong evidence
Blood-based biomarker increasingly used to reduce reliance on invasive lumbar puncture.
Amyloid PETStrong evidence
Confirms amyloid pathology for trial enrollment and diagnosis.
GFAP (plasma)Moderate evidence
Astrocyte activation marker. Emerging non-invasive biomarker.
YKL-40 (CSF)Moderate evidence
Microglial/astrocyte activation marker validated across multiple neurodegenerative diseases.
Active clinical trials
| NCT ID | Drug | Phase | Status | Sponsor |
|---|---|---|---|---|
| NCT05287341 | Anti-tau antibody (JNJ-63733657) | Phase II | Recruiting | Janssen R&D |
| NCT04468659 | Lecanemab extension study | Phase III | Active | Biogen/Eisai |
Related diseases — shared mechanisms
Phase 1 primary cohort + monitored diseases